Benzodiazepines and memory.

T Roth; T Roehrs; R Wittig; F Zorick

doi:10.1111/j.1365-2125.1984.tb02581.x

Home/Archive/PubMed

PubMed · 6151849

Benzodiazepines and memory.

T Roth·T Roehrs·R Wittig·F Zorick

View original source ↗Export metadata ↓

Abstract

Benzodiazepines possess anterograde amnesic properties, disrupting both short-term and long-term memory function. The amount of amnesia is systematically related to dose effects and half-life differences among the benzodiazepines. Memory deficits are found for episodic, semantic, and iconic memory function. The deficits in long-term memory are probably the result of a disruption of consolidation of information in memory and not retrieval from memory. The disruption is produced by rapid sleep onset. Thus the long-term amnesia is really a retrograde effect of sleep and not the anterograde effect of the drug.

Explore related subjects

Amnesia Anti-Anxiety Agents Benzodiazepines Electroencephalography Half-Life Humans Memory Memory, Short-Term Mental Recall Models, Psychological Sleep Time Factors Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

T Roth, T Roehrs, R Wittig, F Zorick. 1984. Benzodiazepines and memory.. https://doi.org/10.1111/j.1365-2125.1984.tb02581.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Effects of dynorphin A-(1-13) on carbon monoxide-induced delayed amnesia in mice studied in a step-down type passive avoidance task.

The effects of dynorphin A-(1-13) on carbon monoxide (CO)-induced amnesia in mice were investigated using a step-down type passive avoidance task. Memory deficiency occurred in mice when training commenced 7 days after CO exposure although it was not produced 1 day after CO exposure. The median step-down latency in the retention test of the CO-exposed group was significantly shorter than that of the control group. Administration of dynorphin A-(1-13) (1.5 nmol/mouse i.c.v.) 15 min before the first training session prolonged the step-down latency in the CO-exposed group. Dynorphin A-(1-13) administered immediately after the first training session or administered 15 min before the retention test also prolonged the step-down latency in the CO-exposed group. To determine whether this effect of dynorphin A-(1-13) was mediated via kappa-opioid receptors, we attempted to block its action using a kappa-opioid receptor antagonist (nor-binaltorphimine). Nor-binaltorphimine (5.44 nmol/mouse i.c.v.) blocked the effect of dynorphin A-(1-13) on delayed amnesia. However, dynorphin A-(1-13) (0.5, 1.5 and 5.0 nmol/mouse) did not facilitate the acquisition of memory in normal mice. These results suggest that dynorphin A-(1-13) modulates the kappa-opioid receptor-mediated opioid neuronal system, and that it ameliorates the disruptive effect of CO on acquisition, consolidation and/or recall of memory.

Amnesia↗

PubMed1995

Memory and consciousness: a selective review of issues and data.

Methods for dissociating and independently studying conscious (explicit) and unconscious (implicit) memory are discussed. Recent work in the field of amnesia is then briefly reviewed, focusing on the question of how clearly the disorder fractionates according to the implicit-explicit distinction. Finally, evidence supporting dual-process models of recognition memory is reviewed, and data suggesting that amnesic patients have relatively spared familiarity-based recognition memory are critically assessed.

Amnesia↗

PubMed1995

Complementary memory storage sites in mice: their development as affected by the competitive NMDA receptor antagonist, CPP.

Bitemporal injections of puromycin consistently induce amnesia of aversive maze learning in mice when administered within 3 days of training. These bitemporal puromycin injections lose their amnestic effectiveness if the latency between training and injection is extended beyond 6 days. Consistent with other evidence, we conclude that in our experimental paradigm, complementary memory storage sites normally develop in additional cerebral areas within 6 days following training. Previous experiments have indicated that the central adrenergic and cholinergic systems are critically involved in this process. We now present evidence that administration of the NMDA receptor antagonist, CPP, blocks the development of these complementary memory storage sites. As suggested by studies of long-term potentiation, NMDA receptor-dependent postsynaptic calcium appears to be essential for the development of these storage sites and indeed to trigger their development.

Amnesia↗